MC
ACHN

Matisse Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Matisse Capital’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-11,315
Closed -$42K – 136
2018
Q1 		$42K Sell
11,315
-124,130
-92% -$406K 0.03% 128
2017
Q4 		$390K Buy
135,445
+18,500
+16% +$67.2K 0.18% 91
2017
Q3 		$525K Buy
116,945
+315
+0.3% +$1.4K 0.25% 70
2017
Q2 		$535K Buy
116,630
+91,200
+359% +$367K 0.27% 67
2017
Q1 		$107K Buy
25,430
+3,000
+13% +$12.5K 0.06% 105
2016
Q4 		$93K Buy
22,430
+10,500
+88% +$55.8K 0.05% 96
2016
Q3 		$97K Buy
+11,930
New +$101K 0.05% 97

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Matisse Capital's ACHN Position: Q2 2018 in Review

Matisse Capital sold out of Achillion Pharmaceuticals (ACHN) in Q2 2018, closing a stake of 11,315 shares — an estimated $42K sold.

Matisse Capital first reported a position in ACHN in Q3 2016 and held it in 7 quarters. The position peaked at $535K in Q2 2017. 124 funds tracked by Wall St. Rank hold ACHN as of Q2 2018.

  • Matisse Capital reported no remaining Achillion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Matisse Capital sold 11,315 Achillion Pharmaceuticals shares in Q2 2018, an estimated $42K.
  • Matisse Capital first reported a position in Achillion Pharmaceuticals in Q3 2016 and held it in 7 quarters.
  • Matisse Capital's Achillion Pharmaceuticals position peaked at $535K in Q2 2017.
  • 124 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2018.

Based on Matisse Capital's 13F filing for Q2 2018, filed 13 Jul 2018.